^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Zepzelca (lurbinectedin)

    i
    Other names: PM1183, PM01183, PM 1183, PM-01183, LY01017, PM-1183, LY 01017, LY-01017, PM 01183
    Company:
    Boryung Group, EMD Serono, Jazz, Key Oncologics, Luye Group, PharmaMar, Specialised Therap
    Drug class:
    Alkylating agent, Apoptosis stimulant, RNA polymerase inhibitor
    Related drugs:
    23h
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, AbbVie | N=50 --> 180
    Enrollment change • Trial initiation date • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
    3d
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, AbbVie | N=27 --> 50
    Enrollment change • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
    4d
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, AbbVie | N=27 --> 180
    Enrollment change • Trial initiation date • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
    6d
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=27, Recruiting, AbbVie
    New P2 trial • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
    10d
    Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers (clinicaltrials.gov)
    P1/2, N=37, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | N=120 --> 37 | Trial primary completion date: Aug 2026 --> Dec 2025
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    berzosertib (M6620) • Zepzelca (lurbinectedin)
    17d
    Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC (clinicaltrials.gov)
    P1/2, N=166, Recruiting, VA Office of Research and Development | Not yet recruiting --> Recruiting
    Enrollment open
    |
    temozolomide • Zepzelca (lurbinectedin) • stenoparib (2X-121)
    18d
    A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Jazz Pharmaceuticals
    New P2 trial
    |
    Imfinzi (durvalumab) • Zepzelca (lurbinectedin)
    1m
    Biomimetic 3D-Bioprinted organoids of thymic epithelial tumors for translational drug screening and biomarker identification. (PubMed, Mater Today Bio)
    Leveraging this biomimetic platform, we conducted high-throughput drug screening and identified lurbinectedin as a potent therapeutic candidate for TETs...Integrating RNAseq data with TCGA survival analysis further identified PBX3, REPS2, and CXCR4 as potential efficacy-predictive biomarkers. This study establishes a translational framework linking 3D bioprinted TET models with biomarker discovery, offering a standardized platform for precision drug screening and mechanistic exploration in thymic epithelial tumors.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • PBX3 (PBX Homeobox 3)
    |
    Zepzelca (lurbinectedin)
    1m
    LiFFT: Lurbinectedin in FET-Fused Tumors (clinicaltrials.gov)
    P1/2, N=63, Recruiting, Children's Hospital of Philadelphia | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial primary completion date
    |
    EWSR1 (EWS RNA Binding Protein 1) • ETV1 (ETS Variant Transcription Factor 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor) • FUS (FUS RNA Binding Protein) • TAF15 (TATA-Box Binding Protein Associated Factor 15) • ETV4 (ETS Variant Transcription Factor 4)
    |
    Zepzelca (lurbinectedin)
    1m
    ISG-TULIPS: Phase II study of lurbinectedin and irinotecan in adult and young adult patients with advanced desmoplastic small round cell tumor (DSRCT) (2024-519261-21-00)
    P1/2, N=20, Recruiting, Italian Sarcoma Group
    New P1/2 trial
    |
    WT1 (WT1 Transcription Factor) • EWSR1 (EWS RNA Binding Protein 1)
    |
    irinotecan • Zepzelca (lurbinectedin)
    2ms
    IDeate-Lung02: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=540, Recruiting, Daiichi Sankyo | Active, not recruiting --> Recruiting
    Enrollment open
    |
    topotecan • Zepzelca (lurbinectedin) • ifinatamab deruxtecan (DS-7300) • Calsed (amrubicin)
    2ms
    EMERGE 101: Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Jazz Pharmaceuticals | Trial completion date: Jun 2027 --> Apr 2028 | Trial primary completion date: Dec 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    Zepzelca (lurbinectedin)